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Abstract: Anderson–Fabry disease (AFD) is a rare disease with an incidenceof approxi-
mately 1:117,000 male births. Lysosomal accumulation of globotriaosylceramide (Gb3) is 
the element characterizing Fabry disease due to a hereditary deficiency α-galactosidase A 
(GLA) enzyme. The accumulation of Gb3 causes lysosomal dysfunction that compromises 
cell signaling pathways. Deposition of sphingolipids occurs in the autonomic nervous 
system, dorsal root ganglia, kidney epithelial cells, vascular system cells, and myocardial 
cells, resulting in organ failure. This manuscript will review the molecular pathogenetic 
pathways involved in Anderson–Fabry disease and in its organ damage. Some studies 
reported that inhibition of mitochondrial function and energy metabolism plays a signif-
icant role in AFD cardiomyopathy and in kidney disease of AFD patients. Furthermore, 
mitochondrial dysfunction has been reported as linked to the dysregulation of the au-
tophagy–lysosomal pathway which inhibits the mechanistic target of rapamycin kinase 
(mTOR) mediated control of mitochondrial metabolism in AFD cells. Cerebrovascular 
complications due to AFD are caused by cerebral micro vessel stenosis. These are caused 
by wall thickening resulting from the intramural accumulation of glycolipids, luminal oc-
clusion or thrombosis. Other pathogenetic mechanisms involved in organ damage linked 
to Gb3 accumulation are endocytosis and lysosomal degradation of endothelial calcium-
activated intermediate-conductance potassium ion channel 3.1 (KCa3.1) via a clathrin-de-
pendent process. This process represents a crucial event in endothelial dysfunction. Sev-
eral studies have identified the deacylated form of Gb3, globotriaosylsphingosine (Lyso-
Gb3), as the main catabolite that increases in plasma and urine in patients with AFD. The 
mean concentrations of Gb3 in all organs and plasma of Galactosidase A knockout mice 
were significantly higher than those of wild-type mice. The distributions of Gb3 isoforms 
vary from organ to organ. Various Gb3 isoforms were observed mainly in the kidneys, 
and kidney-specific Gb3 isoforms were hydroxylated. Furthermore, the action of Gb3 on 
the KCa3.1 channel suggests a possible contribution of this interaction to the Fabry disease 
process, as this channel is expressed in various cells, including endothelial cells, fibro-
blasts, smooth muscle cells in proliferation, microglia, and lymphocytes. These molecular 
pathways could be considered a potential therapeutic target to correct the enzyme in ad-
dition to the traditional enzyme replacement therapies (ERT) or drug chaperone therapy. 
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Anderson–Fabry disease (AFD) is a rare X-linked inborn error of glycosphingolipid 
catabolism that results from mutations in the alpha-galactosidase A gene (GLA) at Xq22 
[1]. 
GLA is a homodimeric glycoprotein that hydrolyses the terminal alpha-galactosyl 
moieties from glycolipids and glycoproteins. This enzyme predominantly hydrolyzes 
ceramide trihexoside, and it can catalyze the hydrolysis of melibiose into galactose and 
glucose. α-Galactosidase A (GLA) catabolizes glycosphingolipids with terminalα-galacto-
syl groups. These glycosphingolipids primarily include globotriaosylceramidebut are also 
present in galabiosylceramide and group B blood antigen. 
AFD is caused by an abnormal glycosphingolipid metabolism due to the lack or ab-
sence of lysosomal α-galactosidase A activity. From this alteration derives a progressive 
accumulation of globotriaosylceramide (Gb3) and its deacylated form globotriaosylsphin-
gosine (lyso Gb-3) in the affected cells of various organs. The main cellular structures in-
volved in this accumulation are represented by endothelial cells, epithelial cells, pericytes, 
myocardial cells, ganglion cells and smooth muscle cells [1]. 
AFD can be considered a multi-organ systemic disease as various studies have shown 
that its main pathological action derives from endothelial damage [2]. This pathology was 
first described in 1898 by Fabry [3] and Anderson [4]. The latter represented a picture of 
angiokeratoma corporis diffusum universal in males. The pathogenesis of AFD has been 
fully described [5,6]. 
Progressive cardiovascular, cerebrovascular and renal dysfunction is related to the 
accumulation of Gb3 and lyso-Gb-3 [7]. Furthermore, studies show that Lyso-Gb3 induces 
an inflammatory and fibrogenic response and promotes the development of proteinuria 
resulting in chronic kidney disease (CKD) and the development of end-stage renal disease 
(ESRD) [8,9]. 
Anderson–Fabry disease is a glycosphingolipidosis characterized by the progressive 
accumulation of glycosphingolipids and the deposition of myelin-like cell inclusions in 
lysosomes. The alpha-galactosidase A enzyme is found in lysosomes and acts to remove 
alpha-bonded galactosyl residues from ceramide trihydroxide, causing the catabolism of 
globotriaosylceramide and related glycosphingolipids [10–12]. 
In Anderson–Fabry disease, the deficiency of the α-galactosidase A leads to an accu-
mulation of Gb3, of its metabolite, globotriaosylsphingosine (Lyso-Gb-3), and of its pre-
cursor metabolite called Gal-Gal-Cer in the lysosomes [11]. 
The abnormal accumulation of Gb3 and Lyso-Gb3 causes cellular dysfunction, result-
ing in the activation of a pathogenetic pathway which is responsible for progressive dam-
age to multiple organs. Hemizygotic males with AFD have a refined accumulation of Gb3 
in the endothelial cells and in the kidneys of Lyso-Gb3 (smooth muscle cells and podo-
cytes) and heart tissue (including valves, cardiomyocytes, nerves, and coronary arteries) 
[8,12,13]. Nevertheless, the role of Lyso-Gb3 analogues in AFD cellular pathology is still 
not fully clear. 
Molecular pathogenesis of Anderson–Fabry disease encompasses several pathologic 
mechanisms involving mitochondrial dysfunction, lysosomal dysfunction, GB3 accumu-
lation, globotriaosylceramide isoforms, and globotriaosylsphingosine accumulation and 
related organ disease, endothelial dysfunction, and autophagy abnormalities (see Figure 
1). Several of these pathogenetic molecular abnormalities may represent possible actual 
and future therapeutic targets. 




Figure 1. Molecular and cellular alterations involved in pathogenesis of Anderson–Fabry disease. 
In this manuscript, we will review the main molecular pathogenetic pathways in-
volved in Anderson–Fabry disease and in its organ damage. 
2. Mitochondrial Dysfunction in Anderson–Fabry Disease 
Deacylated globotriaosylceramide, globotriaosylsphingosine, and a minor additional 
metabolite are dramatically increased in plasma of classically affected male Fabry patients 
and the plasma and tissues of Fabry mice. The accumulation of Gb3 causes a lysosomal 
dysfunction that alters the cell signaling pathway [2,14,15]. Since there is a lysosome–au-
tophagy–mitochondria interaction, the loss of integrity of this interaction is a crucial step 
in organ damage of AFD [16]. Few studies have evaluated mitochondrial function and 
energy metabolism in some aspects of FAD pathology [14,15]. The deposition of Gb3 in 
AFD cardiomyocytes (CM) is responsible for the increased cardiac excitability, with alter-
ation of the calcium activity in the myocardial cells, so as to determine an increased car-
diac excitability [17,18]. 
Myocardial cells, in order to perform their function regularly, need the integrity of 
the mitochondrial cells. Mitochondrial activity is essential for the integrity of energy me-
tabolism to ensure the typical efficiency of myocardial cells. Machann et al. reported that 
inhibition of mitochondrial function and energy metabolism plays a significant role in 
AFD cardiomyopathy [16,19]. Magnetic resonance spectroscopy demonstrated cardiomy-
ocyte involvement and progressive Gb3 storage fibrosis. Some studies have shown a re-
duction in phosphocreatine, Adenosine-di-phosphate (ADP), Adenosin mono-phosphate 
(AMP) and adenosine-tri-phosphate (ATP) in left ventricular mass in patients with AFD 
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[16,18]. Furthermore, electron microscopic evaluation of cardiomyocytes demonstrated a 
reduction in the percentage area of mitochondria in the cytoplasm in proportion to the 
accumulation of Gb3 [20]. A study showed that the reduction in ischemic tolerance ob-
served in patients with AFD is linked to the increased oxygen requirement due to left 
ventricular (LV) hypertrophy [20]. 
Furthermore, progressive lyso-Gb-3 accumulation causes histological damage of kid-
ney cells, resulting from lysosome rupture [9]. Other studies reported that the deposition 
of Gb3 in podocytes has an essential role in the pathogenesis of glomerular damage [21]. 
In addition, phagocytosis abnormalities have been documented through the analysis of 
AFD renal epithelial cells in urine and through evaluation of podocytes in vitro [13]. That 
may represent a pathogenetic basis for AA renal damage. In AFD, microtubule-associated 
protein 1A/1B-light chain 3 (LC3-II) upregulation activity, excessive phagocytosis in renal 
epithelial cells and podocytes, and reduced levels mechanistic target of rapamycin kinase 
(mTOR) may occur in the kidney [13]. Furthermore, the accumulation of Lyso-Gb3 deter-
mines the activation of the inflammatory process in cultured podocytes, as it activates the 
Notch1 signaling pathway [8,22]. Furthermore, upregulation of Notch1 results in in vivo 
podocyte lesions and renal fibrosis. As Notch1 signaling pathways act in various mecha-
nisms of energy metabolism, including glycolysis, Krebs cycle, oxidative phosphoryla-
tion, and glutamine metabolism [8,23], Notch1 disorders can impair mitochondrial me-
tabolism. In Galt Mtg (CAGE-A4GALT) mice, one study observed that bone marrow cells 
in the ascending limb had flattened, round mitochondrial ridges [24]. This finding sug-
gests that mitochondrial dysfunction due to Gb3 accumulation can affect mTA1 function 
and lead to automatic effects, failure of mitochondrial function, and of energy balance. 
MTOR-dependent signaling pathways [24] represent a critical modulator of both the au-
tophagic–lysosomal fusion process and mitochondrial activity. Overall, these data indi-
cate that impaired sphingolipid metabolism can complicate the mitochondrial function of 
kidney cells in FD. 
MTOR, in its active state, is found on the lysosomal surface. This molecule inhibits 
autophagy and lysosomal fusion. Amino acid accumulation in the lysosomal lumen can 
result in the activation of autophagy [25]. Impairment of mTOR activity in fibroblasts and 
AFD podocytes has been reported [25–27]. Other studies have reported that the accumu-
lation of sphingolipid substrates in lysosomes inhibits autophagy–lysosome fusion and 
disrupts mTOR’s activation/inactivation cycle. ATP models control mTOR activity and 
mTOR plays an essential role in maintaining the entry of nutrients and growth factors into 
cells. In response to decreased ATP levels, AMP-activated protein kinase (AMPK) inhibits 
mTOR activity [28]. 
Furthermore, mTOR promotes the dephosphorylation of transcription factor EB 
(TFEB). This molecule also modifies the nuclear structure and the transcription process to 
trigger autophagy [28,29]. Moreover, mTOR regulates mitochondrial metabolism and pro-
motes the translation of mitochondrial-bound proteins encoded in the nucleus, including 
mitochondrial transcription factor 1 (Tfam), cytochrome c oxidase (CoxI) subunit 1, and 
cytochrome c oxidase subunit IV mitochondrial (CoxIV) [29,30]. The activity of cyto-
chrome C oxidase and of the respiratory chain is reduced in fibroblasts of patients with 
AFD [29,30]. Mitochondrial dysfunction, linked to the impairment of the mTOR pathway, 
has been evaluated by in vivo studies, which showed that the dysregulation of the au-
tophagy–lysosomal pathway inhibits the mTOR-mediated control of mitochondrial me-
tabolism in AFD cells [29,30]. 
3. Neuropathological Aspects of Gb3 Accumulation in AA 
Patients with AFD often have cerebrovascular involvement, with the unusual occur-
rence of ischemic stroke at a young age [31–33] and sometimes chronic cerebrovascular 
disease with cognitive impairment [34–37]. Moreover, characteristic findings related to 
peripheral nerve disease such as typical pain, sensory disturbances, and hypohidrosis 
have been reported. MRI of the brain shows more infarcts in the brain, cerebellum, and 
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brainstem in many patients with AFD regardless of the presence of neurological signs, 
and T2 MRI often reveals high-signal areas in the brain’s white matter [34,36–41], some-
times very similar to MRI results of demyelinating disease [42]. 
Cerebrovascular complications are caused by cerebral microvessel stenosis, caused 
by wall thickening resulting from the intramural accumulation of glycolipids, luminal oc-
clusion, or thrombosis [43,44]. One study reported that globotriaosylceramide metabolism 
is also defective in central nervous system (CNS) neurons. In fact, this substance does not 
stain immunohistochemically in the normal brain using a specific antibody [45]. In addi-
tion, in AFD, neuronal swelling due to glycolipid accumulation is scarcely present in some 
restricted nuclei, such as the amygdaloid body, the subiculum, and the dorsal vagus nu-
cleus of the medulla oblongata [44]. The mechanism responsible for the neuronal accumu-
lation of globotriaosylceramide in AFD is not yet fully understood [44]. 
Regarding the involvement of cerebral vessels in AFD, it was observed that many 
segments of the subarachnoidal arteries of medium size (Group II: diameter 100–1000 
mm) are characterized by having a luminal narrowing caused by intimal fibrosis mixed 
with smooth muscle cells (SMC), with membrane strongly undulated and stiffened inter-
nal elastic due to the total or partial replacement of the medial SMC with fibrosis and 
adventitial fibrosis [43]. In the case of episodic and progressive heart failure, it is believed 
that the arterial changes caused by the myocardial accumulation of globotriaosylcer-
amide, typical of the same AFD, can together cause chronic or repeated universal cerebral 
ischemia resulting in multiple infarcts and axonopathic leukoencephalopathy of the deep 
cerebral white matter [43,44]. The latter is nourished by medullary arteries characterized 
by a long course. Thus, moderate to severe multi segmental stenosis and progressive mu-
ral stiffening of the medium-sized subarachnoid arteries appear necessary for dementia 
as a complication of AFD. Furthermore, based on the above, FD dementia is a kind of 
subcortical vascular dementia and the mechanism of preferential involvement of the sub-
arachnoid arteries of group II is an essential issue to be addressed for the future [43]. 
4. Globotriaosylceramide Isoforms and Globotriaosylsphingosine in Organ Damage 
Related to Anderson–Fabry Disease 
Deacylated globotriaosylceramide, globotriaosylsphingosine, and a minor additional 
metabolite have been reported as increased in the plasma of classically affected male 
Fabry patients and plasma and tissues of Fabry mice [45]. Several studies have identified 
the deacylated form of Gb3, globotriaosylsphingosine (Lyso-Gb3), as the main catabolite 
that increases in plasma and urine in patients with AFD. 
Thus, Lyso-Gb3 analogues having various sphingosine modifications are the bi-
omarkers of the disease (See Figure 2). 
Lyso-Gb3 is a valuable biomarker of this disease for diagnosis, the monitoring of dis-
ease progression, and the evaluation of therapeutic efficacy [45,46]. This biomarker has 
analogues with various modifications of sphingosine, and they are also reported as bi-
omarkers of the disease (See Table 1) [9]. Numerous studies have confirmed that such 
glycosphingolipid accumulation [45,46] is significantly associated with the pathogenesis 
of Fabry disease. Although Gb3 is a cellular component, its deposit is responsible for en-
dothelial damage and nephropathy through increased cytokine expression. The increase 
in Lyso-Gb3 also causes injury to glomerular podocytes and sensory neurons and is re-
sponsible for the proliferation of smooth muscle cells. This alteration may be related to 
the vascular defect in Fabry disease. However, to better understand the pathogenesis of 
Fabry disease, it is necessary to investigate the role of the different species of glycosphin-
golipids accumulated in the organs and their action on each organ and tissue. 




Figure 2. Lyso-Gb3 analogues and Gb3 isoform (A: Lyso GB3; B: Gb3 isoform). 
In a study [47], the authors examined the distributions of Gb3 isoforms and Lyso-
Gb3 and its analogues in GLA knockout mice using cell cultures, electrophysiology, real-
time PCR, immunoblot analysis, Mobility Displacement Electrophoretic Assay (EMSA), 
and fluorescence microscopy. Gb3 isoforms were examined, having various fatty acids 
bound to multiple fractions of sphingosine corresponding to Lyso-Gb3 and its four pri-
mary analogues (Lyso-Gb3 (−2), Lyso-Gb3 (+16), Lyso-Gb3 (+18) and Lyso-Gb3 (+34)). 
Ionic fragments derived from the neutral loss of a single galactosyl fragment (162.05 Da) 
from the precursor ion, not components derived from a ceramide moiety, were analyzed. 
The authors found that the ceramide portion of the Gb3 isoforms influenced the evolution 
of several molecular species so that molecules with short, unsaturated, and hydroxylated 
fatty acids linked to sphingosine developed earlier. The authors found that the Gb3 con-
centration in the kidneys was higher than that in the heart and liver in both wild-type and 
GLA knockout mice [47]. 
The mean concentrations of Gb3 in all organs and plasma of GLA knockout mice 
were significantly higher than those of wild-type mice [47]. The distributions of Gb3 
isoforms vary from organ to organ. Various Gb3 isoforms were observed mainly in the 
kidneys and kidney-specific Gb3 isoforms were hydroxylated. In knockout mice, the GLA 
and concentrations of hydrophobic isoforms (e.g., Gb3 (d18: 1-C24: 0)) were higher than 
those of hydrophilic isoforms Gb3 (e.g., Gb3 (d18: 1-C16): 0) in the organs. However, this 
was not observed in plasma. Furthermore, in wild-type mice, concentrations of hydro-
philic isoforms were high in the plasma [47]. 
Unlike that of Gb3, the concentration of Lyso-Gb3 was elevated in the liver but not 
in the kidneys. The mean concentrations of Lyso-Gb3 in all organs and in the plasma of 
GLA knockout mice were significantly higher than in wild-type mice [47]. The Lyso-Gb3 
to Gb3 ratio in plasma was higher than that of organs in both wild-type and GLA-knock-
out mice. The presence of Lyso-Gb3 was higher than that of its analogues in all organs and 
in the plasma of wild-type and GLA knockout mice. Among the analogues of Lyso-Gb3, 
the accumulation of Lyso-Gb3 (−2) and Lyso-Gb3 (+18) were higher than that of the others. 
During an inflammatory process, endothelial cells (ECs) release autacoids such as NO, 
prostaglandins, and a factor that causes relaxation through the hyperpolarization of 
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smooth muscle, whereby the vascular diameter is controlled. Studies have shown that the 
Ca2+activated K+ channel (KCa3.1) plays an essential role in endothelium–dependent re-
sponses during inflammation [47]. 
Mutations in KCa3.1 are responsible for impairing endothelial activity and vascular 
contractility, leading to a predisposition to vascular diseases, including hypertension and 
atherosclerosis. It emerged that Gb3 is responsible for the modulation of the KCa3.1 chan-
nel in MAEC (mouse aortic endothelial cells) of aged Gla knockout mice and MAEC 
treated with Gb3 [47] (see Figure 3). These results were obtained from the analysis of the 
expression and activity of the KCa3.1 channel in both MAEC treated with Gla knockout 
and Gb3. A reduction in protein expression and channel activity was observed in this 
study. This derives from the fact that Gb3 can inhibit the ERK/AP-1 (Extracellular signal-
regulated bkinases) pathway and activate repressor element-1 silencing transcription fac-
tor (REST), with a consequent reduction in the expression of KCa3.1 and associated de-
struction of the channel structures already present. Reduced intracellular PI(3)P (Phos-
phatidylinositol 3-phosphates) levels cause a reduction ofKCa3.1 current in Gb3-treated 
and aged Gla knockout MAECs. From these results, Gb3-induced KCa3.1 channel dys-
function, which may be involved in the endothelial dysfunction of Fabry disease, was ob-
served for the first time [47]. 
 
Figure 3. Summary diagram of the role of KCa3.1 channel as a potential target of AFD treatment. 
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Table 1. Gb3 isoforms and Lyso-Gb3. 
Kidney-Specific Gb3 
(Globotriaosylceramide) Isoforms 
Cardiac Specifics Gb3 
Isoforms 
Lyso-Gb3 Analougues 
Gb3 (d18: 1–C24: 0) Gb3 (d18: 1–C16: 0) Lyso-Gb3 (−2) 
Gb3 (d18: 1–C16): 0)  Lyso-Gb3 (+16) 
  Lyso-Gb3 (+18) 
In Gla knockout mice, at the cellular level, was observed Gb3 accumulated in the 
endothelium, analogous to that observed in Fabry disease. This mechanism can be added 
because reactive oxygen species (ROS) inhibit ERK 1/2 phosphorylation in human endo-
thelial cell. It has also been found that Gb3 induces the generation of ROS in endothelial 
cells. Therefore, the ROS produced by the accumulation of Gb3 could further down-regu-
late p-ERK, with consequent inhibition of the expression of the KCa3.1 channel and po-
tentiate the effect of Gb3. Since there is not yet complete clarity in this regard, the role of 
ROS and Gb3 must be clarified in detail [47,48]. Since inhibition of ERK or PI3K can sup-
press eNOS expression, the action of Gb3 on down-regulated p-ERK and PI3K could con-
tribute to impaired endothelium–dependent relaxation (EDR) function by reducing NO 
production, resulting in endothelial damage [47,48]. 
In addition to the effect of GB3 on KCa3.1 channels, it has been observed that REST 
can decrease the expression of these channels. In fact, the KCa3.1 channels in endothelial 
cells regulate the passage of Ca2+, thus determining the expression of EDR. Therefore, the 
compromise of the KCa3.1 channel alters EDR [47,48]. Consequently, the reduced EDR 
activity found in Gla knockout mice can be caused by various mechanisms: PI3K inhibi-
tion, p-ERK downregulation, REST upregulation, or KCa3.1 channel dysfunction. There-
fore, in light of the scientific evidence through the use of knockout mice, it was observed 
that KCa3.1 deficiency has a severe impact on ACh-induced EDR, with a consequent sig-
nificant increase in arterial blood pressure and an increased risk of atherosclerosis. These 
results could therefore give an explanation for uncontrolled hypertension in Fabry pa-
tients [47,48]. 
In contrast, the KCa1.1 channel, known as the high conductance Ca2+ activated K+ 
channel, is expressed in mouse aortic smooth muscle cells and has been shown to be un-
affected by the effect of GB3. 
In conclusion, the action of Gb3 on the KCa3.1 channel raises essential questions 
about the contribution of this interaction to the Fabry disease process, as this channel is 
expressed in various cells, including endothelial cells, fibroblasts, smooth muscle cells in 
proliferation, microglia, and lymphocytes. In consideration of its essential role in the cel-
lular functions of these cells, it has been suggested that the accumulation of Gb3 of cells, 
including endothelial cells, may be correlated with the progress of Fabry disease. There-
fore, the KCa3.1 channel could be evaluated as a potential therapeutic target for the dis-
ease [46–49]. 
5. Pathogenesis of Endothelial Dysfunction Linked to Gb3 Accumulation 
The link between globotriaosylceramide (Gb3) and globotriaosylsphingosine (lysa-
bilisceramide) and disease severity is not clearly understood. In a study [50], authors ex-
amined some Gb3 isoforms (various fatty acids) and Lyso-Gb3 analogs (various sphingo-
sine alterations) in two types of mouse models of Fabry disease: a background a mixed 
B6/129 or C57BL/6(B6) pure, characterized by prominent cardiac and renal hypertrophy 
and thermal sensitivity deficit. In the two models, the total levels of Gb3 and Lyso-Gb3 in 
the heart, kidney, and dorsal root ganglion (DRG) were similar. The C20 fatty acid isoform 
of Gb3 and some Lyso-Gb3 analogs (+18, +34) showed higher concentrations in Fabry-
B6/129 heart tissue than Fabry-B6. There was no difference in the DRG and in the 
isoforms/analogues of Gb3 and Lyso-Gb3 in the kidneys of the two blocks. The authors 
also reported that Gb3 significantly deposited in DRG mechanoreceptors, representing a 
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subpopulation of sensory neurons, while still performing functions in Fabry disease. In 
non-peptidergic nociceptors, they represent a relevant subpopulation for the disease and 
influence the expression of isolectin-B4 (the marker of non-peptidergic nociceptors) with 
the role of binding and increasing cell size; no accumulation was detected. Authors also 
showed that the different degree of deposition of Gb3 or Lyso-Gb3 can play a significant 
role in the pathogenesis of Fabry disease and that Gb3 and Lyso-Gb3 may not be involved 
in the pathogenetic damage of AFD in all tissues or structures. 
However, endothelial dysfunction represents the main pathological event linking the 
different clinical symptoms of Anderson–Fabry disease. 
Some studies [51,52] conducted on knockout (KO) mice have allowed important in-
sights into the knowledge of the effects of Gb3 accumulation and its relationship with 
progressive endothelial dysfunction and subsequent vasculopathy. 
A study [51] showed the accumulation of Gb3 in the caveolae of aortic endothelial 
cells. This study evaluated the lipid quantity of primary culture mouse aortic endothelial 
cell caveolins isolated from null alpha-Gal A to understand the pathogenesis of Fabry dis-
ease. From the lipid analysis, it was observed that the excessive accumulation of Gb3 in 
the endothelial cells of the alpha-Gal in a mouse aorta in culture was deposited at the level 
of the plasma endothelial membrane. There was also a simultaneous increase in gluco-
sylceramide and lactosylceramide and Gb3 levels in line with age. At the same time, the 
accumulation of globotriaosylceramide (Gb4) isoform in relation to age was analyzed. At 
the level of the caveolar membranes, a progressive increase in the concentration of en-
riched cholesterol and consequent decrease in its levels was also observed, in line with the 
progressive deposition of Gb3. In this study, inhibition of Gb3 with recombinant human 
alpha-Gal A protein or d-treo-ethylenedioxyphenyl-P4, a glucosylceramide synthase in-
hibitor, resulted in increased cholesterol in the caveoles of alpha-deficient mouse aortic 
endothelial cells. In contrast, recombinant human alpha-gall A failed to normalize choles-
terol content. These results demonstrate how the caveolar accumulation of glycosphin-
golipids in an in vitro model of a lysosomal storage disease is responsible for the changes 
in the architecture of the lipid microdomains of the plasma membrane and how these lipid 
alterations may represent one of the possible pathogenetic causes of endothelial damage 
characteristic of Fabry disease. 
Another study [52] used pluripotent stem cells generated from four AFD patients 
(AFD-iPSC) after induced differentiation into vascular endothelial cells (VECs) to better 
understand the relationship between Gb3 accumulation and vascular disease. We modi-
fied the genome using the Clustered Regularly Interspaced Short Palindromic Repeats 
(CRISPR)-Cas9 system to eliminate the GLA mutation or eliminate thrombospondin-1 
(TSP-1). RNA sequencing was used to analyze global transcriptomes between wild-type 
(WT) and post-AFD-VEC. The authors reported that excessive modulation of TSP-1 is in-
volved in VEC dysfunction in AFD. The authors observed alterations in angiogenesis in 
VEC resulting from abnormalities of AFD-iPSC (FD-VEC) even following treatment with 
recombinant α-galactosidase. Curiously, the FD-VECs produced more p-mothers against 
decapentaplegic homolog 2 (SMAD2) and TSP-1 than the wild type (WT)-VECs. The au-
thors also observed an increase in TSP-1 levels in the peritubular capillaries of the kidney 
tissues when performing renal biopsy of patients with AFD. In consideration of the fact 
that inhibition of SMAD2 signaling or knock out of TSP-1 (TSP-1-/AFD-VEC) protects nor-
mal vascular function in AFD-VEC, as well as in gene corrected AFD-VEC, and in light of 
the fact that excessive oxygen consumption is reduced in the TSP-1-/-AFD-VEC, it was 
concluded that the overexpression of TSP-1, resulting from the accumulation of Gb3, is 
more responsible for the observed dysfunction of FD-VEC. These results suggest that re-
duced VEC angiogenesis in peritubular capillaries may represent one of the possible path-
ogenetic alterations responsible for the complications. 
Therefore, Anderson–Fabry disease is characterized by the early development of vas-
culopathy and endothelial dysfunction. 
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A further study [53] set out to better understand the pathological mechanisms of the 
disease by evaluating serum samples obtained from 17 healthy controls, and 15 AFD pa-
tients with and seven without CF. A multiplex ELISA test was performed for 23 different 
angiogenesis markers in pooled samples. Features showing significant differences be-
tween groups were further tested in single models using specific ELISA antibody tests. 
Symmetric Dimethylarginine (SDMA), L-arginine, asymmetric (ADMA), and L-homoargi-
nine (hArg) were analyzed through liquid chromatography-mass spectrometry. Matrix 
metalloproteinase 9 (MMP-9) and angiostatin were elevated in patients with AFD com-
pared to controls regardless of the presence of CF. SDMA concentrations were higher in 
patients with CF. Between L-homoarginine and SDMA (hArg/SDMA) was lower in CF 
patients than in controls. No significant differences were observed between the L-arginine, 
hArg and ADMA groups, although there was a trend towards higher ADMA levels and 
lower hArg levels. A relationship could be identified between renal and cardiac function 
(p = 0.045). The authors concluded that elevated levels of MMP-9 and angiostatin lead to 
increased extracellular matrix turnover in patients with AFD. Furthermore, the alteration 
of SDMA and hArg/SDMA was responsible for endothelial dysfunction in these patients. 
6. Pathogenesis of Lysosomal Damage due to Globotriaosylceramide (Gb3) 
The endothelium regulates vascular smooth muscle tone and, therefore, vascular di-
ameter. It is responsible for the pathogenetic basis of perfusion defects and dysfunction of 
multiple organs, including heart, kidneys, skin, and brain, in individuals with Fabry dis-
ease [46]. 
Endothelial cells release autacoids such as nitric oxide, prostaglandins, and an endo-
thelium-derived hyperpolarizing factor (EDHF) which cause smooth muscle hyperpolar-
ization and relaxation. Intermediate conductance Ca2+-activated K+ channel (KCa3.1) plays 
a crucial role in endothelium–dependent responses, including endothelium–dependent 
hyperpolarization. 
The mutation of KCa3.1 causes the alteration of endothelium–dependent control of 
vascular contractility. This process is responsible for a predisposition to vascular diseases, 
such as hypertension and atherosclerosis [50,54]. 
Moreover, some authors observed that in Human embryonic kidney cells (HEK 
cells), K+ channels, expressed by transfection and not endogenously expressed, are de-
graded. These studies showed that endothelial expression and KCa3.1 activity are re-
duced by GB3 accumulation and that the defect in the synthesis of this channel protein is 
the cause of KCa3.1 downregulation [46]. 
Some authors [49] investigated whether Gb3 induces KCa3.1 endocytosis and degra-
dation. In this study, the authors evaluated the effects of Gb3 on these receptorial struc-
tures. The results have shown that Gb3 is responsible for endocytosis and lysosomal deg-
radation of endothelial KCa3.1 via a clathrin-dependent process. This process leads to en-
dothelial damage. In mouse aortic endothelial cells (MAECs) and human umbilical vein 
endothelial cells treated with Gb3, lysosomal inhibitors seem to inhibit the downregula-
tion of KCa3.1, especially at the level of the plasma membrane. KCa3.1 is not down-regu-
lated by endoplasmic reticulum stress-inducing agents. Gb3 increased the levels of early 
endosome antigen 1 and lysosomal associated membrane protein 2 in MAECs. In MAECs 
from aged α-galactosidase A (GLA)-knockout mice, KCa3.1 expression was downregu-
lated. In these cells, early endosome antigen 1 and lysosomal-associated membrane pro-
tein 2 expression were upregulated. In MAECs from aged GLA-knockout mice, clathrin 
was in the cell border and clathrin knockdown determined the recovery of KCa3.1 expres-
sion. Rab5, an effector of early endosome antigen 1, was upregulated, and Rab5 knock-
down caused regular KCa3.1 expression. 
  
Int. J. Mol. Sci. 2021, 22, 10088 11 of 22 
 
 
7. Molecular Pathogenesis of Renal Involvement in Anderson–Fabry Disease 
The cellular mechanisms of kidney dysfunction in Anderson–Fabry Disease are not 
clearly described. It seems to play a crucial role in kidney injury, one of the programmed 
necrotic cell death pathways as necroptosis [55]. The diagnosis of AFD is often delayed 
because of the heterogeneous phenotype, disease severity variability, and symptoms on-
set. Several studies have shown that patients with rapid progression of kidney disease 
have higher urinary protein to urinary creatinine ratios [56]. Furthermore, pre-existing 
diseases or conditions, such as smoking, hyperlipidemia, or hypertension, may contribute 
to a progressive reduction of GFR [57,58]. However, GLA variants and the environmental 
factors cannot clearly explain the phenotypic variability of AFD. Often, even between the 
same family members with the same pathogenic GLA variant, there is enormous clinical 
variability [58]. 
Podocytes are terminally differentiated cells, so they do not divide; therefore, their 
replacement potential in adults is limited. Deposition of glycosphingolipids in podocytes, 
endothelial cells, and other cell types leads to formation of myelin-like inclusions, which 
are the hallmark of the disease [59,60]. This accumulation results in the fusion of podocyte 
foot processes and clinically in advancing proteinuria. Damaged podocytes detach from 
the glomerular basement membrane lost in the urine. Podocyturia is a representation of 
the clinical severity of Fabry nephropathy [61]. Podocytes detachment and urinary excre-
tion are correlated with reduced adhesion of podocytes to the extracellular matrix due to 
low levels of podocalyxin [62]. Podocyturia disrupts glomerular selectivity, causes albu-
minuria/proteinuria, and leads to glomerulosclerosis and fibrosis [7]. Podocyturia is an 
excellent marker to predict renal involvement; even before that, the albumin/creatinine 
ratio (ACR) changes. Indeed, a positive correlation was found between podocyturia and 
ACR [63]. Despite podocyturia being an early clinical sign of kidney injury and possibly 
serving as a diagnostic test to assess kidney involvement, it is still not regularly used in 
clinical practice. This is because methods for assessing podocyturia are not yet standard-
ized and not available in most clinical settings. 
Receptor interacting serine/threonine kinase 3 (RIPK3) plays an essential role in 
necroptosis. Some authors [57] studied the role of protein phosphokinase RIPK3 in the 
pathogenesis of Fabry nephropathy both in vivo and in vitro. They showed that cell via-
bility of podocytes decreased after Lyso-Gb3 treatment in a dose-dependent manner, with 
increasing RIPK3 expression. Furthermore, increased reactive oxygen species (ROS) levels 
caused by Lyso-Gb3 treatment and their alleviation by GSK’872 (a RIPK3 inhibitor) sug-
gested the presence of oxidative stress via an RIPK3-dependent pathway. RIPK3 inhibitor 
normalized cytoskeleton rearrangement caused by Lyso-Gb3. Injection of Lyso-Gb3 in 
mice induced increase albuminuria and reduced podocytes counts in the glomeruli. In 
conclusion, this study indicated a new pathway in Fabry nephropathy. It showed that 
Lyso-Gb3 caused podocyte loss and subsequent foot process effacement, leading to albu-
minuria, a clinical manifestation of Fabry nephropathy. 
Transforming growth factor-β1 (TGF-β1) and the macrophage inhibitory factor re-
ceptor cluster differentiation 74 (CD74) are implicated in the tissue damage of diabetic 
nephropathy [64]. Globotriaosylsphingosine (Lyso-Gb3) accumulates in the AFD. This bi-
oactive molecule seems to affect the secretion of mediators responsible for glomerular 
damage and, therefore, could play a role in Fabry disease nephropathy. Some authors [64] 
hypothesized that Lyso-Gb3 could be accountable for releasing secondary mediators of 
damage in glomerular podocytes. It has been shown that vitamin D receptor activation 
has nephroprotective actions in diabetic nephropathy. They also want to study whether 
these nephroprotective actions might be applied to Lyso-Gb3. In this study, the authors 
analyzed potential modulation by vitamin D receptor activation of biological activity of 
Lyso-Gb3 in cultured human podocytes. Paricalcitol or calcitriol activates the vitamin D 
receptor and, consequently, maintains normal TGF-β1, CD74, and extracellular matrix in-
duced by Lyso-Gb3. The results demonstrated that paricalcitol, which reduces proteinuria 
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in diabetic nephropathy, has the same action in Fabry nephropathy. In fact, paricalcitol 
causes the interruption of the harmful pathway activated by Lyso-Gb3 in podocytes. The 
authors concluded thatLyso-Gb3 could be responsible for glomerular injury in Fabry dis-
ease, modulating the release of secondary mediators of glomerular injury common to di-
abetic nephropathy. Paricalcitol has a preventive action on this injury pathway activating 
VDR. This study suggests that paricalcitol could have a potential adjunctive role in Fabry 
nephropathy therapy. 
In renal impairment in Fabry disease, podocyturia causes glomerulosclerosis and is 
responsible for kidney disease progression. It is known that podocyte attachment to the 
glomerular basement membrane involves integrins [63,64]. Some authors studied Lyso-
Gb3 actions on integrins in Fabry nephropathy. The αvβ3 integrin, in addition to UPAR, 
causes podocyte detachment and podocyturia. The authors wanted to study if Lyso-Gb3 
modulates αvβ3 expression in podocytes. For this aim, they [65] evaluated in cultured 
human podocytes how Lyso-Gb3 affects the mRNA expression of some genes, in particu-
lar the Integrin Subunit Alpha V (ITGAV) and Integrin transforming growth factor beta 1 
(ITGB3), encoding integrins αv and β3. The results showed that ITGAV and ITGB3 mRNA 
levels were increased in the presence of Lyso-Gb3. The same pattern of gene expression 
was already detected for PLAUR (UPAR). However, these findings are in contrast with 
the subsequently found increase in levels of proinflammatory cytokines and other mark-
ers of podocyte stress (CD80, TGFβ1, CD74, Notch1, and HES). Glycolipid overload in-
duces human podocytes stress; the expression of components of the αvβ3/UPAR system 
is increased in Fabry nephropathy, but this is in contrast with a tardive increased expres-
sion of other mediators of podocyte injury. This suggests a possible therapeutic strategy 
in which the αvβ3/UPAR system may be a target in Fabry nephropathy. 
Lyso-Gb3 is a glycolipid that accumulates in serum in Fabry disease and determines 
increased extracellular matrix synthesis in podocytes. Some authors [8] studied, in cul-
tured human podocytes, how Notch1 responds to Lyso-Gb3 stimulation. High concentra-
tions of Lyso-Gb3, stimulating in podocytes the activation of Notch1 signaling, determine 
increased levels of Notch1 and HES1. HES1 is upregulated in response to Lyso-Gb3. This 
upregulation is inhibited by a specific Notch1 small interfering RNA (siRNA) or γ-secre-
tase inhibitor. The same action was detected on upregulation of Notch1, Notch ligand 
Jagged1, and chemokine (monocyte chemoattractant protein-1 (MCP1), Regulated upon 
Activation, Normal T Cell Expressed and Presumably Secreted (RANTES) expression. 
NFκB contributes to the activation of Nocht1-mediatedinflammatory response. Notch1 
siRNA prevents the Lyso-Gb3-induced activation of nuclear factor kappa B (NFκB), and 
the NFκB inhibitor prevents Lyso-Gb3 action on chemokine upregulation. Furthermore, 
it was observed [66] that in podocytes, Notch1 induces a fibrogenic response and Notch 
siRNA inhibits Lyso-Gb3 activity on fibronectin mRNA. These data are supported by the 
presence of different molecules, as such active Jagged1, HES1 and Notch1, in Fabry kidney 
biopsies. The authors concluded that Lyso-Gb3 is a promoter of a Notch1-mediated in-
flammatory process, and it stimulates fibrogenic responses in podocytes; these Lyso-Gb3 
mediated responses may have a role in the pathogenesis of Fabry nephropathy. 
Genetic modifiers associated with the specific clinical presentation of Anderson–
Fabry Disease have not yet been evaluated with genome-wide association studies 
(GWAS). Some studies reported the association of variants of the gene involved in inflam-
matory and thrombosis/hemostasis mechanisms with a higher risk of cerebral lesions and 
stroke in Fabry patients [8,67,68]. Alcohol Dehydrogenase 4 (ADH4) (rs1126670, 
rs1126671, rs2032349) and Alcohol Dehydrogenase 5 (ADH5) (rs2602836), gene variants in 
human alcohol dehydrogenase family genes, have been related to AFD progression [66]. 
Some authors hypothesized that some gene modifiers are likely to contribute to organ 
involvement and disease progression as the clinical presentation itself varies widely be-
tween family members with identical pathogenic GLA variant. Another field of investiga-
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tion is the analysis of transcriptomics focusing on some selected urinary miRNA charac-
terized by a higher or lower degree of expression in AFD. A decrease in certain miRNA 
species, such asmiR-29 and miR-200, has been associated with renal fibrosis prior to the 
onset of pathological albuminuria [69]. Some serum miRNAs such asmiR-1307-5p, miR-
21-5p, miR-152-5p, and miR-26a-5p have been reported as significantly down-regulated 
in Anderson–Fabry patients. Furthermore, miR-19a-3p and miR-486-5p have been re-
ported to be down-regulated in subjects with AFD [70]. 
Concerning epigenomics, the real burden of DNA and/or histone modifications on 
the AFD progression and particularly on nephropathy remains unclear. Few studies ana-
lyzed epigenetic changes in AFD [71,72]. In Fabry patients, high concentrations of the 
methylated/non-methylated Gb3 isoform were found in urine compared to controls char-
acterized by the absence of trace amounts of the methylated Gb3 isoform in control urine 
samples [73]. 
A study [73] evaluated non-methylated Gb3 isoforms normalized to creatinine. Au-
thors studied these biomarkers in Fabry patients compared to healthy controls and eval-
uated correlations between biomarker urinary excretion and age, gender, treatment, and 
genotype of patients. They analyzed, with a tandem mass spectrometer, urine samples 
from 150 Fabry patients and of 95 healthy controls. The authors reported some significant 
correlations between Gb3 isoform concentrations, gender, and treatment. In five patients 
with the late-onset cardiac mutation, p.N215S was found abnormal concentrations of 
methylated Gb3 isoforms compared to their non-methylated homologues. 
Glycosphingolipid biomarkers, such as globotriaosylceramide (Gb3) isoforms, glo-
botriaosylsphingosine (Lyso-Gb3) and related analogues, and galabiosylceramide (Ga2) 
isoforms and analogues were found to be abnormally increased in urine and plasma of 
Fabry patients; these molecules could be used as specific biomarkers of the disease. An-
other study [74] reported that the methylated Gb3isoforms are particularly useful for 
screening Fabry patients who present late-onset cardiac variant mutations and renal var-
iants. 
8. Molecular Pathogenesis of Cardiac Involvement in Anderson–Fabry Disease 
Cardiac involvement is a common finding in Anderson–Fabry disease, both in hem-
izygous men and heterozygous women, and it also represents a significant cause of mor-
bidity and mortality. Accumulation of globotriaosylceramide regards various heart cells, 
including conduction system cells, valvular fibroblasts, cardiomyocytes, endothelial cells 
of heart vessels, and vascular smooth muscle cells. The typical finding of cardiac involve-
ment of AFD is cardiac hypertrophy that may worsen, developing an impairment of con-
tractility and diastolic filling impairment. Other possible cardiac involvement signs are 
atrioventricular conduction disturbances, coronary insufficiency, arrhythmias, and valvu-
lar involvement. 
Gb3 storage by itself is not enough to explain the degree of cardiac hypertrophy, con-
duction abnormalities and other cardiac manifestations. In a patient with Fabry disease 
with a remarkably increased cardiac mass, the autopsy showed a low contribution (1–2%) 
of the accumulated material to severe heart hypertrophy [75]. Some studies reported that 
that storage induces progressive lysosomal and cellular malfunctioning that, in turn, acti-
vates common signaling pathways leading to hypertrophy, apoptosis, necrosis, and fibro-
sis. Energy depletion has recently been proposed as a possible pathogenetic background 
in numerous metabolic and even sarcomeric hypertrophic cardiomyopathies, including 
Fabry disease [76]; in fact, impairment of energy management was observed in skin fibro-
blasts [77]. It seems that, in addition to mechanical storage, biochemical factors might also 
play a role. In patients with neuronal ceroid lipofuscinosis, another lysosomal storage dis-
ease has been described as mitochondrial disfunction, so some authors examined mito-
chondrial function in fibroblasts from patients with AFD [78]. This study showed a signif-
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icant reduction of respiratory chain enzymes I, IV, and V activities in AFD-cells. The mi-
tochondrial marker enzyme citrate synthase activity demonstrated that mitochondrial re-
covery was normal, and cellular protein content was not significantly different. ADP and 
AMP concentrations were substantially lower in AFD-cells. ATP was slightly but not sig-
nificantly reduced. Thus, it seems reasonable that organ damage in AFD may not only be 
explained by mechanical storage of glycosphingolipids, but lysosomal storage material 
may be responsible for mitochondrial dysfunction with a reduction of respiratory chain 
enzyme activities and subsequent lower levels of energy-rich phosphates. 
Inflammation might play a critical role in the development of cardiac changes in 
Fabry disease. In end-stage cardiomyopathy in patients with Fabry disease, fibrosis in the 
left ventricle (but not in the right ventricle) is a common finding [77,78]. A study evaluated 
cardiomyocyte dysfunction in patients with Fabry disease and cardiomyopathy. The au-
thors showed that intracellular accumulation of GB3 is associated with oxidative damage 
of proteins and DNA, which leads to cardiomyocyte dysfunction and death; this study 
also revealed the presence of hypertrophic and disorganized cardiomyocytes, cells death 
through apoptosis, high expression of inducible nitric oxide synthase and nitrotyrosine, 
and evidenced glycosphingolipid accumulation in endomyocardial biopsies [79]. Moreo-
ver, these results showed that several cytokines levels were increased in the serum of 
Fabry patients. Among these wereIL-1β, TNF-α, IL-6, monocyte chemoattractant protein-
1 (MCP-1), intercellular adhesion molecule-1, and soluble vascular adhesion molecule 
[80]. These findings indicate that proinflammatory cytokines might play a role in the pro-
gression of Fabry disease-related cardiomyopathy. The functions of proinflammatory cy-
tokines in cardiomyopathy may differ between patients with and without Fabry disease. 
The autopsy from patients with Fabry disease showed various apoptotic myocytes 
on caspase-3-positive cytoplasmic staining, and in the myocardium, there was also a mild 
T-lymphocyte interstitial infiltrate [81]. Inflammatory macrophages seem to have an es-
sential role in myocardial injury; they were observed in some endomyocardial biopsies 
from patients with Fabry disease. Moreover, the same study reported Gb3 accumulation 
in myocytes of both atria and ventricles and in endothelial cells, coronary arteries, aorta, 
valve tissue, and smooth muscle cells. The presence of extensive areas of myocyte disarray 
associated with fibrosis has also been reported [80,81]. 
9. Molecular Mechanisms and Possible Therapeutic Targets 
α-Gal gene is a 12kb comprising seven exons, located on the X chromosome (Xq22.1), 
and its mutation causes Fabry disease. Over 100 different mutations have been described 
up to now. Among these, most are missense mutations but insertions, deletions, and RNA 
processing defects caused by aberrant splicing have also been reported [82]. These muta-
tions are responsible for reduced or absent enzyme activity. 
Glycosphingolipids such as globotriaosylceramide (Gb3) are components of the 
plasma membrane that are degraded in the lysosome. Several hydrolyzing enzymes, in-
cluding α-Ga, are necessary for the correct catabolism of glycosphingolipids. The progres-
sive accumulation of the incompletely degraded substrate Gb3 in the cells is due to a de-
ficiency of this hydrolase [82]. The deposits lead to cellular dysfunction or degeneration; 
GB3 is accumulated within multi vesicular bodies or intracytoplasmatic masses. It seems 
that intracellular Gb3 storage triggers a series of pathological mechanisms correlated to 
the progressive impairment of the respective tissue and organ function with severe con-
sequences. Recent advances in molecular biology and genetic engineering have enabled 
the development of causal therapies for storage diseases [82]. A possible therapeutic strat-
egy is supplying the deficient human enzyme, which is replaced by infusion of recombi-
nant enzyme preparation. Two randomized trials of enzyme replacement therapy in 
Fabry disease have been conducted [83]. Both enzyme therapies were well tolerated and 
seemed to be effective in catabolizing the lipid deposits. Using agalsidase β, the authors 
showed reductions of capillary endothelial cell Gb3 storage in the heart. There were no 
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functional effects reported; thus, the clinical relevance of these results is unknown. Schiff-
mann et al. [83], using agalsidase α, showed a significant decrease in QRS duration, sug-
gesting a reduction in left ventricular hypertrophy. Preliminary data of further studies in 
Mainz and London using agalsidase α confirmed these findings. They showed a signifi-
cant decrease in left ventricular mass and an increase in diastolic function and cardiac 
output [84]. 
Chemical chaperones are molecules that bind and stabilize misfolded proteins in the 
endoplasmic reticulum (ER), thereby stimulating regular trafficking and contributing to 
increased residual activity [85]. This subclass of therapy is being developed for a range of 
disease, including Anderson–Fabry Disease, Gaucher disease, Pompe disease, Batten dis-
ease, mucopolysacchirodosis type IIIC, and GM1 andGM2 gangliosidosis [86]. Migalastat 
[87] has been evaluated in both ERT-naïve and ERT-treated A patients with treatment re-
sulting in increased and sustained endogenous α-GAL activity, with the maintenance of 
kidney function and a reduction in the left ventricular mass index [88,89]. Reduction in 
Lyso-Gb3 levels of up to 45% has been demonstrated in ERT-naïve adult patients. How-
ever, not all patients experienced an increase in activity of the enzyme and a reduction of 
Lyso-Gb3 levels [90]. This raises the caveat that this form of therapy exerts efficacy only 
in specific mutations of AFD. It is estimated that only 35–50% of AFD mutations are ame-
nable to migalastat use with367 amenable and 711 non-amenable mutations [91]. 
Substrate reduction therapy (SRT) acts on the downstream effects of enzyme defi-
ciency by reducing substrate production resulting from the defective enzyme before ac-
cumulation, thereby reducing synthesis to a level compatible with residual clearance [92]. 
Given the mechanism of action, these therapies have particular promise in lysosomal stor-
age disorders (LSD). GCS inhibitors limit conversion of ceramide to glycosphingolipid, 
eventually leading to a reduction of Gb3 production. Lucerastat (N-butyl deoxy galac-
tonojirimycin), an imino-sugar inhibitor of GCS, lowered Gb3 in kidneys of Fabry mice 
null for α-GAL [93]. No severe adverse effects were observed in two separate randomized, 
double-blind, placebo-controlled, single and multiple ascending dose studies on lucera-
stat [94]. A subsequent open-label, randomized study of 10 patients with AFD who re-
ceived lucerastat at 1 g twice daily demonstrated a mean reduction of 55% in Gb3 levels, 
along with being well-tolerated over 12 weeks [93]. 
10. Autophagy Abnormalities in Molecular Pathogenesis of Anderson–Fabry Disease 
Degradation of metabolic wastes and damaged cell elements such as mitochondria 
inside the cell is a critical process to maintain cellular homeostasis and respond to envi-
ronmental stress. Macro autophagy or autophagy is a cell process that sequesters cyto-
plasmic cargos into double-membrane compartments (autophagosomes) and then directs 
them towards lysosomes [95]. Defects in autophagy process may cause the accumulation 
abnormal materials in tissues, and this abnormality seem to be the pathogenestic basis of 
some human cardiovascular diseases [25,95]. Lysosome-associated membrane protein 2 
(LAMP-2) is the crucial mediator of the process of interplay between autophagy process 
and lysosomes. 
Furthermore, one study reported how a well-functioning lysosome/autophagic path-
way is fully involved in the vascular architecture and function [25]. In Anderson–Fabry 
disease, ischemic stroke represents an expression of organ damage of the disease and 
pathological studies in AFD patients reported that VSMC proliferation is induced in cer-
ebral arteries and that there is a relationship between autophagy defects and small vessel 
disease [25,95]. In animal models of VSMC autophagy-related 7 knockout mouse Atg7−/−, 
some authors reported an increase in medial thickening of the aorta due to VSMC hyper-
trophy 15. 
A study [96] analyzed the biological features of LAMP-2-deficient mice and cultured 
cells. LAMP-2-deficient mice at 9–24 months of age showed medial thickening with lu-
minal stenosis due to proliferation of vascular smooth muscle cells (VSMC) in muscular 
arteries. Ultrastructural analysis of VSMC revealed various autophagic vacuoles scattered 
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throughout the cytoplasm, suggesting impaired autophagy of long-lived metabolites and 
degraded organelles (i.e., mitochondria). These findings indicate that LAMP-2 deficiency 
leads to arterial medial hypertrophy with the phenotypic conversion of VSMC, resulting 
from age-dependent accumulation of cellular waste generated by aberrant autophagy. 
These pathogenetic mechanisms could also be involved in vascular complications of An-
derson–Fabry Disease. 
A study [97] by means of an experimental mouse model of Fabry disease, alpha-ga-
lactosidase A deficiency, studied brain pathology in mice models of AFD aiming to ex-
plain the real role of the autophagy–lysosome pathway. Authors reported that alpha-ga-
lactosidase A-deficient mouse brains showed a high density of punctate perinuclear im-
munoreactivity for the autophagy marker microtubule-associated protein light-chain 3 
(LC3) in the parenchyma of several brain regions and increased vascular immunoreactiv-
ity for lysosome-associated membrane protein-1 (LAMP-1). Ultrastructural analysis also 
showed endothelial cell inclusions with electron densities and a pronounced accumula-
tion of electron-dense lipopigment [97]. These findings indicate widespread neuropathol-
ogy and focused axonal neurodegeneration in alpha-galactosidase A-deficient mouse 
brain in association with disruption of the autophagy–lysosome pathway and may offer 
the basis for future mechanistic assessment of the contribution of the autophagy–lysosome 
pathway to neuropathologic phenotype of AFD [96]. 
The role of autophagy disorders in AFD does not only involve neurological compli-
cations of the disease but it also regards the development of progressive renal damage. 
Histological studies suggest that the accumulation of Gb3 in podocytes plays an important 
role in the pathogenesis of glomerular damage. Some authors [22] studied a human po-
docyte model of Fabry’s disease by combining RNA interference technology with lentivi-
ral transduction of human podocytes. Knockdown of a-galactosidase A expression re-
sulted in diminished enzymatic activity and slowly progressive accumulation of intracel-
lular Gb3. Interestingly, these changes were accompanied by an increase in autophago-
somes as indicated by an increased abundance of LC3-II and a loss of mTOR kinase activ-
ity, a negative regulator of the autophagic machinery. These data suggest that dysregu-
lated autophagy in a-galactosidase A-deficient podocytes may be the result of deficient 
mTOR kinase activity. This finding links the lysosomal enzymatic defect in Fabry’s dis-
ease to deregulated autophagy pathways and provides a promising new direction for fur-
ther studies on the pathomechanism of glomerular injury in Fabry patients. 
11. Conclusions 
Anderson–Fabry disease is an X-linked lysosomal storage disease caused by absent 
or reduced α-galactosidase A activity and the consequent accumulation of GB3 in endo-
thelial cells [98]. GB3 accumulation is associated with several clinical signs and symptoms, 
such as cardiac problems, renal failure, and central nervous system pathology [98]. The 
location of lyso-GSL in plasma is unclear. Lyso-Gb3 was detected associated with albumin 
but not in lipoproteins [13]. Furthermore, α-galactosidase-A activity is inhibited by Lyso-
Gb3, increasing GB3 storage. Lyso-Gb3 also affects smooth muscle cell proliferation; other 
studies suggested that globotriaosylsphingosine stimulates cardiomyocytes and vascular 
smooth muscle cell proliferation [99]. A study conducted on human podocytes hypothe-
sized that Lyso-Gb3 could have a role in the pathogenesis of Fabry nephropathy [64]. 
Lyso-Gb3 affects the production of TGFβ, invariant chain (CD74), and extracellular matrix 
(fibronectin and type IV collagen). These components are involved in the fibrotic re-
sponse, which leads to kidney failure [64]. In the plasma of Fabry patients, Lyso-Gb3 was 
shown to inhibit NO synthase. This could contribute to the vasculopathy and cardiac 
symptoms in Fabry patients [100,101]. These effects are contrasted by paricalcitol or cal-
citriol, which activates the vitamin D receptor. Another study demonstrated, using human 
podocytes, that Lyso-Gb3 also induced inflammatory response. The γ-secretase inhibitor 
IX (GSI IX) could inhibit activation of NF-κB, derived by the Notch1 signaling pathway. 
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This pathway induced monocyte chemoattractant protein-1 (MCP-1/CCL2) in human po-
docytes [8]. Furthermore, in DC, monocytes and Peripheral blood mononuclear cells 
(PBMCs) from Fabry patients showed high levels of pro inflammatory cytokines. Some 
authors studied GB3 in monocyte-derived dendritic cells and macrophages, adding GB3 
and simultaneously inhibiting α-Gal. From these results, GB3 seems to be a toll like recep-
tor 4 (TLR4) recognized ligand [102]. Preventing GB3 clearance led to an increased pro-
duction of IL-1β and TNFα. Furthermore, blocking TLR4 with antibodies reduced the cy-
tokine induction mediated by GB3 [102]. However, it is not yet clear if (lyso-)GB3 also has 
a modulating action on immunity via type II NKT cells [101,103,104]. 
Considering that lyso-GSL could be toxic, it would be interesting to attempt to reduce 
the levels of this molecule. A way to achieve this result would be to reduce their accumu-
lation with substrate reduction therapy (SRT). In conclusion, in addition to future gene 
therapies to correct the enzyme defect, SRT is a potential therapeutic strategy, as well as 
the traditional enzyme replacement therapies (ERT) or drug chaperone therapy (PCT) 
[105]. 
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AFD Anderson Fabry disease 
Gb3 Globotriaosylceramide 
GLA Alpha-galactosidase A 
ESRD End-stage renal disease 
ADP Adenosine-di-phosphate 
AMP Adenosin mono-phosphate 
ATP adenosine-tri-phosphate 
LC3-II Microtubule-associated protein 1A/1B-light chain 3 
MTOR Mechanistic target of rapamycin kinase- 
AMPK AMP-activated protein kinase 
TFEB Transcription factor EB 
Tfam Mitochondrial transcription factor 1 
CoxI Cytochrome c oxidase subunit 1 
Cox IV Cytochrome c oxidase subunit IV 
ECs Endothelial cells 
KCa3.1 Ca2+ activated K+ channel 
MAEC Mouse aortic endothelial cells 
PI(3)P Phosphatidylinositol 3-phosphates 
ROS Reactive oxygen species 
ERK 1/2 Extracellular signal-regulated kinases 
VECs Endothelial cells 
EDR Endothelium–dependent relaxation 
CRISPR)-Cas9 Clustered Regularly Interspaced Short Palindromic Repeats Cas 9 
TSP-1 Thrombospondin-1 
SMAD2 p-mothers against decapentaplegic homolog 2 
SDMA Symmetric Dimethylarginine 
ADMA L-arginine, asymmetric 
hArg L-homoarginine 
MMP-9 
Metalloproteinase 9 Pathogenesis of lysosomal damage due to globotriaosylcer-
amide (Gb3) 
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EDHF Endothelium-derived hyperpolarizing factor 
KCa3.1 Ca2+-activated K+ channel 
HEK cells Human embryonic kidney cells 
ACR Albumin/creatinine ratio 
RIPK3 Receptor Interacting Serine/Threonine Kinase 3 
TGF-β1 Transforming growth factor, beta 1 
CD74 cluster differentiation 74 
ITGAV Integrin Subunit Alpha V 
ITGB3 transforming growth factor beta 3, 
PLAUR (UPAR) 
Plasminogen Activator, Urokinase Receptor (rokinase plasminogen activator 
surface receptor) 
MCP1 Monocyte chemoattractant protein-1 
RANTES Regulated upon Activation, Normal T Cell Expressed and Presumably Secreted 
REST Repressor element-1 silencing transcription factor  
GWAS genome-wide association studies 
ADH4 Alcohol Dehydrogenase 4 
ADH5 Alcohol Dehydrogenase 5 
LAMP-2 Lysosome-associated membrane protein 2 
VSMC Vascular smooth muscle cells  
GSI IX γ-secretase inhibitor 
PBMCs Peripheral blood mononuclear cell 
TLR4 Toll-like Receptor 4 
SRT substrate reduction therapy 
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